From the company's SEC filings: the last twelve months to 30 Sep 2026, built from its 10-K and 10-Q reports. P/E and market value use the 17 Nov 2026 close, with the latest quarter's diluted share count; P/E is market value over net income, which stays right through a stock split. Growth compares with the twelve months a year earlier.
50-day average $963.08 · 200-day average $876.85 · 52-week closing range $725.17 – $1,105.04
| Name | Close | 1M | 1Y | 5Y | P/E | Stage |
|---|---|---|---|---|---|---|
| Merck | $143.37 | -1.8% | +54.4% | +73.6% | 144.8 | 2 |
| Johnson & Johnson | $278.70 | +9.1% | +39.6% | +70.7% | 42.4 | 2 |
| Eli Lilly | $1,415.55 | +12.6% | +38.5% | +442.0% | 45.9 | 2 |
| Gilead Sciences | $170.26 | +9.0% | +37.2% | +152.4% | loss | 2 |
| Regeneron Pharmaceuticals | $957.76 | +21.1% | +36.0% | +49.2% | 21.0 | 2 |
| Amgen | $457.93 | +5.9% | +34.0% | +122.5% | 26.6 | 2 |
| Elevance Health | $433.93 | +1.3% | +31.1% | +1.0% | 18.4 | 2 |
| Bristol Myers Squibb | $61.35 | +2.7% | +31.1% | +3.2% | 13.6 | 2 |
| AbbVie | $292.82 | +2.6% | +25.1% | +149.5% | 50.2 | 2 |
| Vertex Pharmaceuticals | $534.20 | +6.9% | +23.1% | +183.8% | 34.3 | 2 |
| UnitedHealth | $389.68 | -2.9% | +21.6% | -13.2% | 22.1 | 2 |
| Thermo Fisher | $686.79 | -0.5% | +21.1% | +7.8% | 36.0 | 2 |
| Pfizer | $28.47 | -3.8% | +13.5% | -44.0% | 40.6 | 2 |
| CVS Health | $85.81 | -7.1% | +9.4% | -7.5% | 10.0 | 3 |
| Medtronic | $102.32 | +8.0% | +6.3% | -13.2% | 25.1 | 2 |
| HCA Healthcare | $501.19 | +9.2% | +5.0% | +105.5% | 16.1 | 1 |
| Danaher Corporation | $225.77 | -1.4% | +2.4% | -17.8% | 36.8 | 2 |
| Stryker Corporation | $317.54 | +7.8% | -11.8% | +21.2% | 33.7 | 1 |
| Abbott Laboratories | $104.71 | -0.2% | -19.5% | -18.6% | 38.7 | 2 |
| Intuitive Surgical | $430.53 | +0.9% | -21.3% | +19.1% | 51.2 | 1 |
← All US stocks and world indices · NSE stocks